Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial. Jacobs JW, Booth GS, Stephens LD, Tormey CA, et al. Lancet 2024;404:433.

Read + Share

Amedeo Smart

Independent Medical Education

Jacobs JW, Booth GS, Stephens LD, Tormey CA, et al. Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial. Lancet 2024;404:433.
PMID: 39097393